Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic

Colic, Infantile Clinical Trial

Official title:

A Double-blind, Mylti-center, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05512234
• Other study ID #: CSUB0197
• Status: Recruiting
• Phase: N/A
• Start date: July 13, 2022
• Est. completion date: August 31, 2024

Study information

• Verified date: September 2023
• Source: BioGaia AB
• Contact: Caroline Linninge, PhD
• Phone: +46 703811942
• Email: cli[@]biogaia.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, multi-center, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying time.

Description:

Prevalence of infantile colic varies according to the definition used but estimates range between 5 % and 26 % of the infant population. To differentiate colic from other, more serious conditions it should be characterized by several clinical features. Infant colic is often accompanied by flushing the face, frown, tensing of the abdomen, clenching of the fists, and drawing up the leg, frequent, prolonged, and intense crying or fussiness in a healthy infant. Even though infant colic is benign and usually self-limiting condition it is a source of major distress for the infant, parents, family, and health care givers. Despite infant colic occurs frequently, little agreement has been reached on the definition, pathogenesis, or the optimal management strategy for infant colic. Recent systematic reviews and meta-analyses showed that probiotic L. reuteri DSM 17938 supplementation significantly lowered the number of hours of crying and fussing daily. A significant peak effect was seen at 3 weeks in most studies. Interestingly, babies with infant colic were found to have increased evidence of gut inflammation, as evidenced by high levels of the antimicrobial peptide fecal calprotectin; also, the levels of fecal calprotectin declined significantly as the condition resolved.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 102
• Est. completion date: August 31, 2024
• Est. primary completion date: May 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Weeks to 8 Weeks

Eligibility

Inclusion Criteria:

1. Aged between 3-8 weeks at screening.

2. Gestational age 37+0 weeks - 42+0 weeks at birth.

3. Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.

4. Parents/caregivers/legal guardians are >18 years.

5. Exclusively or predominantly breastfed infants (> 50 % breast fed).

6. Willing to maintain current feeding patterns (not change formula/not change ratio of formula:breast milk etc.).

7. Readiness and the opportunity for parents/caregivers/legal guardians to fill out a study diary, questionnaires.

8. Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents/caregivers/legal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hour period should show 3 or more hours of crying/fussing time.

9. Parents/caregivers/legal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator.

10. Parents/caregivers/legal guardians willing and able to give informed consent for their and their infant's participation in the study.

11. The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 4 (Day 8), and Visit 6 (Day 22).

12. Infant is considered healthy, in the opinion of the investigator following physical exam. Exclusion criteria

1. Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk > 8 times daily, projectile, bilious or bloody emesis).

2. Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container > 12x in breastfed and >5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents/caregivers/legal guardians.

3. Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.

4. Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.

5. Infants with reported exposure to oral and/or systemic antibiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.

6. Infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to Screening Visit (V1) and throughout the study period.

Related Conditions & MeSH terms

• Colic
• Colic, Infantile

Intervention

Dietary Supplement:
• L. reuteri
Dietary supplementation with drops containing L. reuteri once daily for 21 consecutive days
• Placebo
Dietary supplementation with placebo drops identical to those containing L. reuteri once daily for 21 consecutive days

Locations

Country	Name	City	State
Ireland	Atlantia Clinical Trials	Cork
Sweden	Clinical Trail Consultants AB	Uppsala

Sponsors (3)

Lead Sponsor	Collaborator
BioGaia AB	Atlantia Food Clinical Trials, CTC Clinical Trial Consultants AB

Countries where clinical trial is conducted

Ireland,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Crying and fussing time	Change in daily crying and fussing time measured by Baby Day Diary	From baseline to Day 7
Secondary	Crying and fussing time	Change in mean daily crying and fussing time measured by Baby Day Diary	From baseline to Day 3, Day 5, Day 14, Day 21
Secondary	Crying time	Change in mean daily crying time measured by Baby Day Diary	From baseline to Day 3, Day 5, Day 7, Day 14, Day 21
Secondary	Number of responders	Proportion of responders defined as reduction of daily average crying time with 50 % compared to baseline	From baseline to Day 3, Day 5, Day 7, Day 14, Day 21
Secondary	Family quality of life (family QoL)	Change in family QoL measured by the PedsQL Family Impact Module (Acute) - Total Score	From baseline to Day 7 and Day 21
Secondary	Sleeping time	Change in mean sleeping time measured by Baby Day Diary	From baseline to Day 3, Day 5, Day 7, Day 14, Day 21
Secondary	Maternal depression	Change in maternal depression measured by the Edinburgh Postnatal Depression Scale Total Score	From baseline to Day 7 and Day 21